We recently published our piece Top 8 Cheap Stocks Under $5 That Smart Investors Are Secretly Buying. To read the full article, head on to Top 5 Cheap Stocks Under $5 That Smart Investors Are Secretly Buying. Here, we turn our focus to Iovance Biotherapeutics Inc. (NASDAQ:IOVA) as one of the stocks gaining attention, and take a closer look at why it stands out in today’s market.
In the world of investing, timing has always been everything—but history quietly suggests that it is often uncertainty that creates the most profitable entry points. Seasoned market observers who have spent decades navigating cycles—from the dot-com boom to the 2008 financial crisis and the pandemic-driven rally of 2020—understand one recurring truth: when headlines are dominated by geopolitical tension and macroeconomic ambiguity, the smart money begins positioning early. That backdrop now frames the renewed interest in penny stocks, a segment often overlooked yet historically capable of delivering outsized returns when sentiment shifts.
A Market Rally Built on Fragile Optimism
The events of April 2026 offered a classic example of how quickly sentiment can pivot. Following developments in the ongoing US–Israel–Iran conflict, Wall Street experienced a sharp surge after signals of a potential ceasefire emerged. The reaction was immediate and telling. The Dow Jones Industrial Average jumped nearly 870 points in a single session, while the S&P 500 and NASDAQ Composite extended their rally to fresh record highs. For market veterans, this kind of synchronized movement across major indexes typically signals a broad-based shift in risk appetite, not merely a short-term bounce.
Yet beneath the surface, the situation remains layered with complexity. While diplomatic progress injected optimism into global markets, the continuation of the US naval blockade on Iranian ports served as a stark reminder that geopolitical risk has not disappeared—it has simply evolved. This dual narrative—hope on one side and caution on the other—has created a fertile environment for high-risk, high-reward investment strategies, particularly in the realm of small-cap stocks and penny stocks under $5.
Why Penny Stocks Are Back in Focus
It is not by coincidence that penny stocks to buy now have re-entered the conversation. Historically, these stocks tend to outperform during early-cycle recoveries, when capital begins rotating away from defensive large-cap names toward more speculative growth opportunities. This pattern has repeated itself across multiple decades. During the post-2009 recovery, for instance, small-cap equities significantly outpaced their large-cap counterparts, driven by faster earnings growth and greater sensitivity to improving economic conditions.
The recent correction in the Russell 2000, which tracks small-cap performance, further reinforces this setup. After gaining more than 8% earlier in the year, the index slipped into correction territory amid escalating tensions in the Middle East. For experienced analysts, such pullbacks are rarely viewed as structural breakdowns. Instead, they are often seen as reset points—moments where valuations become more attractive and future upside begins to rebuild.
What makes the current landscape particularly compelling is the contrast between short-term disruption and long-term projections. Consensus estimates compiled by Bloomberg suggest that small-cap companies could deliver earnings growth of over 40% in the next 12 months, far outpacing the expected growth of large-cap stocks. This divergence is not trivial. It highlights a structural opportunity that aligns closely with one of the oldest investing principles: growth follows neglect.
The Hidden Advantage of Market Dislocations
One of the lesser-discussed realities of financial markets is that geopolitical crises often accelerate capital reallocation. When uncertainty rises, institutional investors reassess risk exposure, sometimes exiting crowded trades and reallocating funds into underpriced segments of the market. This is where best penny stocks 2026 begin to attract attention—not because they are inherently safer, but because they offer asymmetrical upside when sentiment normalizes.
Veteran financial writers often recall how, during previous periods of instability, the most significant gains were not found in the obvious blue-chip names but in smaller, overlooked companies that quietly built momentum while the broader market hesitated. It is a dynamic that continues to play out today, as investors search for high growth penny stocks, undervalued small-cap stocks, and cheap stocks with high upside potential.
Positioning for the Next Wave
Against this backdrop, the question is no longer whether volatility will persist—it almost certainly will. The more relevant question is how investors can position themselves to benefit from it. For those willing to accept higher levels of risk, top penny stocks to invest in now represent a calculated bet on recovery, innovation, and shifting market dynamics.
This is precisely the lens through which the current list of opportunities should be viewed. These are not merely low-priced stocks; they are companies operating at the intersection of market disruption, investor sentiment, and forward-looking growth narratives. Each carries its own risks, but collectively, they reflect a broader theme that has defined some of the most profitable periods in market history: the willingness to invest when uncertainty is still unfolding.
CHECK THIS OUT: Top 10 Stocks Dominating Today’s Market andTop 10 Hottest Stocks Dominating the Market Today.
Our Methodology
To identify the top 8 cheap stocks under $5 that smart investors are secretly buying, stocks trading under $5 were screened using Finviz, filtered for strong analyst sentiment, and selected based on at least 30% upside potential as of April 17, with additional emphasis on recent news catalysts and ranking by projected price appreciation.
Top 5 Cheap Stocks Under $5 That Smart Investors Are Secretly Buying
3. Iovance Biotherapeutics Inc. (NASDAQ:IOVA)
Stock Price: $3.86
Upside Potential: 107.25%
Iovance Biotherapeutics Inc. has emerged as one of the more momentum-driven names within the penny stock segment, supported by tangible clinical progress and a rapidly expanding commercial footprint. The company’s flagship therapy, Amtagvi, has become the central pillar of its growth narrative, particularly following its FDA approval for certain cancer indications. What differentiates Iovance from many of its peers is not just the existence of a promising therapy, but the speed at which it is translating clinical success into revenue growth.
In its most recent reporting period, the company posted a 30% sequential increase in revenue, reaching $87 million and surpassing market expectations. This performance was largely driven by strong demand for Amtagvi, with US revenue alone contributing $65 million. Such figures are critical in the biotech space, where the transition from development-stage to commercial-stage operations often determines long-term viability. Analysts, including Jefferies, have reinforced their bullish stance by highlighting that competitive risks are already factored into current valuations, shifting the focus toward execution and market expansion.
Looking ahead, the company’s global strategy adds another layer of upside. With approvals already secured in Canada and regulatory reviews underway in major markets such as the UK, Australia, and Switzerland, Iovance is positioning itself for broader international penetration. The potential expansion of Amtagvi into lung cancer indications further extends its addressable market, creating a multi-year growth runway. For investors searching for top penny stocks to buy now with triple-digit upside, Iovance represents a case where clinical validation, revenue growth, and geographic expansion converge into a single, coherent investment thesis.
YOU MUST READ THIS: Top 10 Best Stocks Analysts Are Bullish On Right Now
Disclosure: No material interests to disclose. This article was originally published on Global Market Bulletin.
